AMERICAN
PSYCHOLOGICAL
ASSOCIATION

April 13, 2009

The Honorable Patrick Leahy, Chairman
Committee on the Judiciary
United States Senate
Washington, DC 20510

Dear Mr. Chairman:

On behalf of the American Psychological Association (APA), I am writing to offer our strongest possible endorsement for A. Thomas McLellan, Ph.D., to serve as Deputy Director of the Office of National Drug Control Policy. Dr. McLellan has dedicated his scientific career to improving our understanding of substance use disorders and their treatment through innovative and groundbreaking research, and we are confident that he will bring that same level of commitment to the Office of National Drug Control Policy.

Highly regarded for his scholarship, Dr. McLellan has authored hundreds of research articles during his career and over the past decade has served as Associate Editor and Editor-in-Chief of the most important scientific journals in the addiction provider community. Beyond his vast contributions to our understanding of the diagnosis and treatment of substance use disorders, Dr. McLellan has demonstrated remarkable leadership in the translation of those research findings into practical applications. Perhaps best known for the development of the Addiction Severity Index and Treatment Services Review, clinical instruments used to measure multiple aspects of substance use and treatment efficacy, Dr. McLellan literally gave them away, and they are now the world's most widely used tools in the treatment of drug and alcohol addiction, having been translated into 20 languages.

Dr. McLellan has labored tirelessly to remove the stigma associated with drug addiction by likening it to many other chronic health conditions. As such, his seminal report in the Journal of the American Medical Association was the first to demonstrate that success rates for the management of substance use disorders are on par with success rates for the management of asthma, diabetes, and hypertension. Dr. McLellan's passion for educating the public and his pragmatic approach to policy evolved from trying to help those afflicted with drug addiction in his own family. With that level of personal involvement, Dr. McLellan has a well-earned reputation as a tireless and selfless public health advocate who simply wants to know what treatments work and how to effectively implement them.

Serving as the Chief Executive Officer of the not-for-profit Treatment Research Institute, Dr. McLellan has led an unparalleled research enterprise. But unlike so much research

750 First Street, NE
Washington, DC 20002-4242
(202) 336-6080
(202) 336-6069 (Fax)
nanderson@apa.org

Norman B. Anderson, Ph.D.
Chief Executive Officer

that becomes archived in academic medical school libraries, Dr. McLellan has nurtured relationships with individuals and organizations to extend the reach of those scientific findings to benefit millions of American lives. As just one example, in collaboration with the Partnership for a Drug Free America, his "Time to Talk" series is serving as an enormously successful prevention and intervention program to help parents help their children to stay drug free.

In closing, we are delighted that President Obama has nominated a scientist of Dr. McLellan's stature, who also has such a visionary and practical approach to rationale policy-making, to serve as Deputy in the Office of National Drug Control Policy. Thank you for your serious consideration of Dr. McLellan for this position. The field of drug abuse treatment and the public health of our nation will be very well-served by Dr. McLellan's appointment.

Sincerely,

Norman B. Anderson, Ph.D.
Chief Executive Officer

May 6, 2009

The Honorable Patrick Leahy, Chairman
U.S. Senate Judiciary Committee
224 Dirksen Senate Office Building
Washington, DC 20510

Dear Senator Leahy,

As a former Director of the Office of National Drug Control Policy, I would like to state my strong support for the confirmation of Dr. Thomas McLellan as Deputy Director of the Office.

Dr. McClellan brings extraordinary expertise in the areas of addiction and treatment. Not only has he served as Editor in Chief of the highly respected Journal of Substance Abuse Treatment, but his work includes twenty-five years at Veterans Administration hospitals aiding in treatment, and he currently is professor of Psychiatry at the University of Pennsylvania. He is also CEO of the Treatment Research Institute in Philadelphia, a nonprofit organization dedicated to reducing dependence on alcohol and drugs.

Dr. McLellan is a leader in developing strategies assessing addiction and building treatment success. He has regularly advised ONDCP, as well as the World Health Organization and the Partnership for a Drug Free America.

As President Obama has pointed out in his statement nominating Dr. McLellan, Dr. McLellan's Addiction Severity Index and Treatment Services Review, measuring the severity of addiction and the effectiveness of treatment, have been adopted around the world, and have dramatically improved protocols to help patients. These measures have given a quantifiable, scientific basis to what has hitherto been a nebulous gauging, Dr. McLellan's nomination will bring as sharp focus on the need to expand science based treatment.

Just recently, Dr. McLellan's Journal of Substance Abuse Treatment printed an article with peer-reviewed findings that Internet based video substance abuse counseling is as effective as traditional group counseling even for patients with severe opiate addictions. It is this sort of creative, forward-thinking science that Dr. McLellan has spearheaded that can begin to make a dent in the nation's treatment gap.

According to SAMHSA, 23 million individuals are chronically addicted while less that four million currently receive treatment. Dr. McLellan, together with ONDCP Director-designate Gil Kerlikowske, will bring badly needed leadership in reducing this disparity which has greatly impacted the crime, job losses, and broken families in America today.

I urge prompt confirmation of Dr. McLellan.

Sincerely,

Barry R. McCaffrey
General, USA (Ret.)
Director, Office of National Drug Control Policy
1996-2001

Thanks for your continued brilliant public service!

National Association of State Alcohol and Drug Abuse Directors, Inc.

President
Flo Stein
North Carolina

First Vice President
Joe M. Hill
Arkansas

Vice President for Internal Affairs
J. Kent Hunt
Alabama

Vice President for Treatment
Emilio Vela, Jr.
Washington

Vice President for Prevention
Debbie Synhorst
Iowa

Immediate Past President
Barbara Cimaglio
Vermont

President NDIIC
Stephenie Colston
Florida

Secretary
Michael Botticelli
Massachusetts

Treasurer
Karen M. Carpenter-Palumbo
New York

Regional Directors

Michael Botticelli, MA
Region I
Karen M. Carpenter-Palumbo, NY
Region II
TBA
Region III
Donna Hillman, KY
Region IV
Theodora Binion-Taylor, IL
Region V
Terri L. White, OK
Region VI
David Dickinson, KS
Region VII
JoAnne Hoesel, ND
Region VIII
Renée Zito, CA
Region IX
Bethany Gadzinski, ID
Region X

Interim Executive Director
Robert I.L. Morrison

May 7, 2009

Senator Patrick Leahy
Chairman
Senate Judiciary Committee
224 Dirksen Senate Office Building
Washington, DC 20510

Senator Jeff Sessions
Ranking Minority Member
Senate Judiciary Committee
152 Dirksen Senate Office Building
Washington, DC 20510

Dear Chairman Leahy and Ranking Member Sessions:

On behalf of the National Association of State Alcohol and Drug Abuse Directors (NASADAD), and our component organizations the National Prevention Network (NPN), and National Treatment Network (NTN), thank you for your leadership on the Senate Judiciary Committee. We appreciate your work and stand ready to continue our partnership on issues within the Committee's jurisdiction.

We are writing to express our full support of the nomination of Dr. A. Thomas McLellan, Ph.D. to serve as the next Deputy Director of the Office of National Drug Control Policy (ONDCP). We are hopeful that the Committee will soon consider this important nomination and recommend action that will lead to a quick confirmation process.

Dr. McLellan has dedicated his career to developing innovations and knowledge that have increased our understanding about the addiction field. For example, Dr. McLellan's research helped educate the public regarding the fact that addiction is a chronic illness that requires comprehensive and holistic care – including medications – along with supportive services that extend beyond the initial phase of treatment. In turn, more people now understand that treatment for substance use disorders leads to equal if not better outcomes when compared to other diseases.

Dr. McLellan and his colleagues also created the Addiction Severity Index (ASI), a measurement instrument that is widely used for clinical assessment and research purposes. States appreciate the development of tangible tools that can help providers ensure clinically appropriate care.

Finally, Dr. McLellan has worked with a number of NASADAD members to examine State systems and administrative mechanisms to improve service delivery. For example, Dr. McLellan has worked with States to develop contracting tools that help promote performance, outcomes and accountability. One of NASADAD's top public policy priorities is to "Implement an Outcome and Performance Measurement Data System." We agree that the States and federal government should continue to partner to develop State-specific solutions that improve the lives of the people we serve.

In sum, we strongly support the nomination of Dr. McLellan to serve as the next Deputy Director of ONDCP. We look forward to working with you as the nomination process moves forward. Should you have any questions, or require additional information, please do not hesitate to contact me at (202) 293-0090 x106 or email rmorrison@nasadad.org.

Sincerely,

Robert I.L. Morrison
Interim Executive Director

HARVARD LAW SCHOOL

Hauser Hall 522 • Cambridge, Massachusetts 02138

PHILIP B. HEYMANN
James Barr Ames Professor of Law
Director of Center for International Criminal Justice

[redacted]

06 May 2009

The Honorable Patrick J. Leahy, Chairman
The Honorable Arlen Specter
The Honorable Jeff Sessions, Ranking Member
U.S. Senate Committee on the Judiciary
224 Dirksen Senate Office Building
Washington, D.C. 20510

Dear Senators Leahy, Specter, and Sessions:

I am writing to strongly recommend the confirmation of Dr. A. Thomas McLellan for the number two position, the Deputy, in ONDCP. I have come to know Dr. McLellan well and I am convinced that he would be a superb addition to ONDCP.

Dr. McLellan and I served together on the board of directors of Drug Strategies, a nonprofit research institute that identifies and promotes more effective approaches to the nation's drug abuse problems. Based on research Dr. McLellan had supervised at TRI on the increasing use of the internet to sell psychoactive drugs without prescription to young people, Drug Strategies and the Center for Criminal Law at Harvard Law School, along with Dr. McLellan, created a private-public working group to address this problem which had grown, almost unchallenged, to the point where about 10% of high school seniors had used a prescription narcotic within a year of the question being asked.

Dr. McLellan, Mathea Falco, and I brought together distinguished researchers, government officials from every relevant agency, key congressional staff, and high level representatives of credit card companies, internet service providers, and private carrier companies for a series of meetings at Harvard. The recommendations we developed, and circulated to the attendees for comments, became the subject of our testimony before the Judiciary Committee in May, 2007.

Dr. McLellan is a distinguished academic and a leader in the field of addiction research who combines that knowledge with a real understanding of how to bring it to bear on issues of public policy. He brings a rare combination of theory and practice that is urgently needed in rethinking our approach to drug abuse in this country.

I did not know Dr. McLellan when I was Assistant Attorney General in charge of the Criminal Division or Deputy Attorney General, but I wish I had. I would have wanted to work with him on the most serious questions of drug policy. He will be a superb addition to the Office of National Drug Control Policy and will be a real help to this committee as it continues its attention to these issues. I recommend him to you with great enthusiasm.

Sincerely,

Philip B. Heymann

cc: The Honorable Herb Kohl
The Honorable Dianne Feinstein
The Honorable Russell D. Feingold
The Honorable Charles E. Schumer
The Honorable Richard J. Durbin
The Honorable Benjamin L. Cardin
The Honorable Sheldon Whitehouse
The Honorable Ron Wyden
The Honorable Amy Klobuchar
The Honorable Edward E. Kaufman
The Honorable Orrin G. Hatch
The Honorable Charles E. Grassley
The Honorable Jon Kyl
The Honorable Lindsey Graham
The Honorable John Cornyn
The Honorable Tom Coburn

INTEGRITY HOUSE

Board of Trustees

Matthew J. Chanin, CFA, *Chair*
Prudential Financial, Inc.

Joseph W. Walsh, *Vice Chair*
MCJ Amelior

Darrell Terry, *Secretary*
Newark Beth Israel Medical Center

Ronald K. Andrews
Prudential Investment Management

Kenneth A. Arlein
J.H. Cohn, LLP

Maurice J. Brown
Verizon

Ron Christian
Christian Love Baptist Church

Mary M. Deatherage
Solomon Smith Barney

Robert J. Del Tufo, Esq.
Skadden, Arps, Slate, Meagher & Flom

Daniel DeTrolio
Hartz Mountain Industries

Michael Festa, Ph.D.
Essex County Health Department

Margaret Johnson, R.Ph.
Horizon Blue Cross Blue Shield of NJ

Cheryl Ann Kennedy, MD
NJ Medical School – UMDNJ
Department of Psychiatry

David H. Kerr
Integrity, Inc.

Deirdre Malloy
Century 21 Gemini LLC Realty

Barbara L. Melone
Newark Alliance

Tom Moran
PSE&G

Mary Elizabeth O'Connor
Educational Consultant

Geoffrey S. Perselay, Esq.
Correctional Health Services, LLC

John Clinton Reynolds, Jr.
Pastor, Allen A.M.E. Church

Edward D. Roberts, Ph.D.
Living Waters Christian Center

Mary E. Rone

Joseph G. Sandman, Ph.D.
Seton Hall University

Kenneth J. Smith
Torcon, Inc.

May 12, 2009

Senator Patrick Leahy
Chairman
Senate Judiciary Committee
224 Dirksen Senate Office Building
Washington, DC 20510

Dear Chairman Leahy,

I am writing to convey Integrity, Inc. strong support for the nomination of Dr. Tom McLellan for the position of Deputy Director of the National Office of Drug Control Policy (ONDCP).

As one of the leading researchers in the alcohol and other drug policy arena, Dr. McLellan's work at the Treatment Research Institute (TRI) has conducted cutting edge research that demonstrates that addiction is a treatable brain disease with outcomes equal to or better than other chronic illnesses. Dr. McLellan has also been at the forefront of engaging states in implementing pay for performance criteria for the purchase of public sector addiction treatment services that have yielded improved quality of care while reducing costs.

Dr. McLellan and his colleagues have also created measurement instruments such as the Addiction Severity Index (ASI) and the Treatment Services Review. These instruments have been translated into over 20 languages and are the most widely used instruments of their kind in the world. The instruments have been used to evaluate a wide variety of therapies, medications and interventions in the treatment of alcohol and drug dependence.

In conclusion, we believe Dr. McLellan will make an excellent ONDCP Deputy Director and we look forward to working with you in securing his nomination.

Sincerely,

David H. Kerr
President and CEO
Integrity, Inc.

Integrity, Inc. • 103 Lincoln Park • PO Box 510 • Newark, New Jersey 07101

Newark (973) 623-0600
fax (973) 623-1862

Secaucus (201) 583-7100
fax (201) 583-7114

carf Accredited

Commission on Accreditation of Rehabilitation Facilities

Adult Residential Treatment | *Adolescent Residential Treatment* | *Corrections Residential Treatment* | *Partial Day Treatment* | *Adult Opioid Treatment* | *Prevention Services* | *Outpatient Treatment*

CADCA®

May 13, 2009

The Honorable Patrick Leahy
433 Russell Senate Office Building
Washington, DC 20510

Dear Senator Leahy:

On behalf of Community Anti-Drug Coalitions of America (CADCA) and our more than 5,000 coalition members nationwide, I would like to express our strong support for Dr. A. Thomas McClellan's swift confirmation as Deputy Director of the Office of National Drug Control Policy (ONDCP). Throughout Dr. McClellan's stellar research career in alcohol, other drug policy and addiction, he has been widely recognized as one of the premier experts at the forefront of understanding the science behind the disease of addiction.

Dr. McClellan is not only the Chief Executive Officer at the Treatment Research Institute in Philadelphia, but a Professor of Psychiatry at the University of Pennsylvania, a psychologist, and has published more than 400 articles and chapters on addiction research. Two of his primary contributions to science include the Addiction Severity Index, and the Treatment Services Review, both of which have been translated into over 20 languages and widely used throughout the world.

Dr. McClellan is universally respected by the prevention and treatment fields as a result of his profound work to reveal that addiction is a brain disease that can be treated like other chronic illnesses, with successful outcomes. CADCA enthusiastically supports Dr. McClellan's nomination and strongly urges you to see that he is favorably considered and promptly confirmed as the Deputy Director of the ONDCP. Thank you for considering our views on this important nomination.

Sincerely,

Arthur T. Dean
Major General, U.S. Army, Retired
Chairman and CEO

Sue Thau
Public Policy Consultant

cc: Bruce Cohen

Community Anti-Drug Coalitions of America
625 Slaters Lane, Suite 300, Alexandria, VA 22314
P 703-706-0560 **F** 703-706-0565 1-800-54-CADCA cadca.org

NATIONAL ASSOCIATION OF DRUG COURT PROFESSIONALS
NADCP

4900 Seminary Road, Suite 320
Alexandria, VA 22311
Phone:703.575.9400
Fax:703.575.9402
www.nadcp.org

BOARD OF DIRECTORS

Thomas Alexander
San Diego, CA
Hon. Barbara Brugnaux
Terre Haute, IN
Peter Carlisle
Honolulu, HI
Hon. John Creuzot
Dallas, TX
Hon. Rogelio Flores
Santa Maria, CA
Norma Jaeger
Boise, ID
Scott Henggeler, Ph.D.
Charleston, SC
Earl Hightower
Studio City, CA
Hon. Jamey H. Hueston
Baltimore, MD
Hon. Kent Lawrence
Athens, GA
Mike Loeffler
Bristow, OK
Lars Levy
Morgan City, LA
Attorney General Patrick Lynch
Providence, RI
Hon. Melanie May *(Emeritus)*
West Palm Beach, FL
Wanda Moore
Trenton, NJ
Connie Payne
Frankfort, KY
Hon. Louis Presenza *(Emeritus)*
Philadelphia, PA
Hon. William Ray Price, Jr.
Jefferson City, MO
Hon. Robert Rancourt
Center City, MN
Larry Robinson
Newport News, VA
Hon. Robert Russell *(Emeritus)*
Buffalo, NY
Terree Schmidt-Whelan
Tacoma, WA
Hon. John R. Schwartz
Rochester, NY
Hon. Chuck Simmons *(Chair)*
Greenville, SC
Hon. Keith Starrett
U.S. District Court, MS
Hon. Jeff Tauber *(Emeritus)*
Berkeley, CA
Lee Webber
Honolulu, HI
Hon. Robert Ziemian
Boston, MA

CHIEF EXECUTIVE OFFICER

West Huddleston

May 14, 2009

The Honorable Patrick Leahy
Chairman
Committee on the Judiciary
United States Senate
Washington, DC 20510

The Honorable Jeff Sessions
Ranking Member
Committee on the Judiciary
United States Senate
Washington, DC 20510

Dear Chairman Leahy and Ranking Member Sessions,

On behalf of the over 22,000 judges, prosecutors, public defenders, probation and law enforcement officers, court administrators, substance abuse and mental health treatment professionals, and community leaders the National Association of Drug Court Professionals represents, it gives me great pride to strongly support the nomination of Dr. Thomas McLellan for the position of Deputy Director of the White House Office of National Drug Control Policy.

As a Professor of Psychiatry at the University of Pennsylvania School of Medicine and the cofounder of the Treatment Research Institute, a not-for-profit research and evaluation institute in Philadelphia where much of the leading research on Drug Court has been conducted, Dr. McLellan is at the forefront of the movement to improve substance abuse and treatment assessments.

Dr. McLellan's long established expertise in assessing the scientific and social complexities of addiction, coupled with his innovative, collaborative approach to engineer and improve effective substance abuse treatment modules, has helped transform our nation's criminal justice and healthcare systems. He truly understands that a strong relationship between treatment and enforcement, along with improved science and administrative structures, are key components to abolishing the drug epidemic in this country.

The nomination of Thomas McLellan presents an opportunity for the White House Office of National Drug Control Policy to stem the tide of substance abuse and crime by implementing a policy that incorporates science, treatment, prevention, and enforcement. Dr. McLellan is the right choice to help achieve these goals and his expedient confirmation is soundly endorsed by the National Association of Drug Court Professionals. Thank you for your continued leadership and for considering this letter of support.

Sincerely



West Huddleston
Chief Executive Officer

NADCP

Center Point, Inc.
CORPORATE OFFICE
135 PAUL DRIVE
SAN RAFAEL, CA 94903
P 415 492 4444 F 415 492 8844
CPMAIL@CPINC.ORG

May 17, 2009

Senator Patrick Leahy
Chairman, Senate Judiciary Committee
224 Dirksen Senate Office Building
Washington, DC 20510

Dear Chairman Leahy,

Please accept this letter in full support of the confirmation of Dr. A. Thomas McLellan as the Deputy Director of the Office of National Drug Control Policy.

Over the course of his more than thirty-year career, Dr. McLellan has made many significant contributions to the addiction and treatment field. I am familiar with Dr. McLellan through his work at the Treatment Research Institute (TRI) and through the application of his research in influencing policy and treatment. Dr. McLellan is an excellent choice for this position. He has been a long-term advocate of addressing addiction through access to appropriate outcome driven treatment. His research has contributed to our understanding that addiction is a treatable chronic disease and that reducing the demand for drugs will lead to sustainable outcomes that benefit the individual, families, and communities as a whole. Dr. McLellan's perspective highlights the importance of education, prevention, intervention, and treatment as the most effective means of reaching these goals.

As the Chief Executive Officer of Center Point, Inc., I have developed and implemented effective treatment alternatives to incarceration for over thirty years. Dr. McLellan's research and the measurement tools created by TRI, such as the Addiction Severity Index, have made significant contributions to the development of effective therapies and interventions in the treatment of addiction.

I believe that Dr. McLellan will make an excellent Deputy Director of ONDCP and, on behalf of Center Point, I strongly support his nomination. Please contact me if further information would be helpful.

Sincerely,

Sushma D. Taylor, Ph.D.
Chief Executive Officer

nfia
National Families in Action

May 20, 2009

The Honorable Patrick Leahy
Chairman
Committee on the Judiciary
United States Senate
Washington, DC 20510

The Honorable Jeff Sessions
Ranking Member
Committee on the Judiciary
United States Senate
Washington, DC 20510

Dear Chairman Leahy and Ranking Member Sessions:

In behalf of parents across the nation, with whom we have worked since our founding in 1977 to help prevent the initiation of alcohol, tobacco, and other drug use by children and adolescents, we write to wholeheartedly endorse the nomination of A. Thomas McLellan to serve as Deputy Director of the Office of National Drug Control Policy. He will be a wonderful leader at ONDCP and as Deputy Director will help advance the field even more than he already has.

We knew of his work beforehand and have been delighted to work with Dr. McLellan since 2000, when he began to teach at our Addiction Studies Program for Journalists, which we co-sponsor with Wake Forest University School of Medicine. The program's goal is to provide journalists with a basic understanding of the science that underlies drug abuse and addiction and help them build relationships with scientists who can assist them with future stories. In 2005, we added two additional partners, Dr. McLellan's Treatment Research Institute and the National Conference of State Legislatures, to extend this program to state policy makers. Dr. McLellan serves on the faculty for this program as well. He is a superb researcher and a pioneer in establishing effective ways to treat addiction, has led and contributed much to the field, and has helped both journalists and state policy makers gain an understanding of addiction and how to effectively treat it. He has also done much to improve the ease with which parents with an addicted child can find appropriate treatment.

We are very grateful to President Obama for nominating Dr. McLellan to this position and urge that he be approved as quickly as possible. The nation needs his wisdom and guidance. Thank you for your leadership and for considering this letter of support.

Sincerely,

President and CEO
National Families in Action

Parent Corps USA Drug Prevention Starts Here!

www.parentcorps.org • www.nationalfamilies.org • www.addictionstudies.org
P.O.Box 133136 · Atlanta, GA 30333-3136 · **404-248-9676**

MCV Campus

Virginia Commonwealth University

Institute for Drug and Alcohol Studies

McGuire Hall, B08
1112 East Clay Street
P.O. Box 980310
Richmond, Virginia 23298-0310

804 828-8633
Fax: 804 828-7862
TDD: 1-800-828-1120

May 25, 2009

Hon. Patrick Leahy, Chairman
Hon. Jeff Sessions, Ranking Member
Hon. Oren Hatch
Hon. Arlen Specter
U.S. Senate Committee on the Judiciary
224 Dirksen Senate Office Building
Washington, DC 20510

Dear Senators Leahy, Sessions, Hatch and Specter.

I take this opportunity to express my strong support for the early confirmation of Dr. A. Thomas McLellan whose nomination for service as Deputy Director of ONDCP is before the Committee. As a former Deputy Director of the predecessor White House Office of Drug Abuse Policy (1977-1979) I well understand the complexities faced by the office in balancing the competing agendas of the various federal agencies and community and professional organizations. Dr. McLellan's willingness to consider, and ability to understand those disparate views will place him in a unique position to guide the establishment of an appropriate Strategy which has been the congressional mandate of the office since the mid-1970's.

Dr. McLellan's leadership of the Treatment Research Institute has resulted in the establishment of the most widely used instruments in the world for measuring the effectiveness of treatment, and allowed informed decisions to be made by treatment providers and governmental agencies on the best methods of transferring research findings to competent health care practitioners and health authorities in order to develop informed policy.

His recognition of excellence by major professional societies and international medical associations speaks to the wide respect in which he is held both nationally and internationally.

Dr. McLellan's participation in discussions leading to this committee's deliberations and the ultimate enactment of one of the most important pieces of addiction treatment legislation of the century, the Drug Addiction Treatment Act of 2000, provides an example of his ability to work with a consortium of interests to develop policy in the best interests of the public health and safety.

It is with sincere enthusiasm that I support Dr. McLellan's nomination and encourage you to consider it favorably at the earliest possible time.

Sincerely,

Charles O'Keeffe
Professor Epidemiology and Community Health
VCU School of Medicine

an equal opportunity/affirmative action university

TASC | Administrative Offices • 1500 North Halsted • Chicago, IL 60642
(312) 787-0208 • (312) 787-9663 fax • www.tasc.org

May 29, 2009

The Honorable Patrick Leahy
U.S. Senate Committee on the Judiciary
433 Russell Senate Office Bldg
Washington, DC 20510
Fax (202) 224-3479

RE: Letter of Support for A. Thomas McLellan

Dear Senator Leahy:

I am writing in support of President Obama's recent appointment of A. Thomas McLellan as the new Deputy Director of the Office of National Drug Control Policy (ONDCP).

Dr. McLellan is one of the nation's leading experts on drug and alcohol policy, one whose decades of experience and perspective will be critical assets in addressing the debilitating, costly impact of addiction on our country.

As a respected psychologist and behavioral researcher, McLellan is committed to the use of evidence-based strategies. He understands the need for collaboration by professionals in various health-related disciplines and governmental agencies. In 1992, he co-founded the non-profit Treatment Research Institute (TRI), an addiction research and development organization dedicated to the science-driven transformation of addiction policy and treatment that we in the field have come to rely on and trust.

McLellan will focus on demand reduction strategies with the capacity to prevent and treat substance abuse and addiction early in its progression. He understands that the nation's overreliance on incarceration and acute care addiction treatment approaches has not appropriately or adequately addressed our drug and alcohol problems. His strong leadership on these issues will advance the mission of the Office.

Since 1976, TASC, Inc. of Illinois (Treatment Alternatives for Safe Communities) has worked with people who have alcohol, drug, and mental health problems and who are chronic users of the courts, jails, prisons, and foster care. We have seen the trends in public health and justice over the years and advocated for creative, fair, and cost-effective programs and policies to anticipate and reverse these trends.

On behalf of TASC and the nearly 30,000 individuals we serve each year, we respectfully support the confirmation of Dr. McLellan as Deputy Director of ONDCP.

Sincerely,

Melody M. Heaps
President

The Partnership for a Drug-Free America®

June 10, 2009

The Honorable Patrick Leahy
Chairman
Senate Committee on the Judiciary
Washington, DC 20510

The Honorable Jeff Sessions
Ranking Member
Senate Committee on the Judiciary
Washington, DC 20510

Dear Chairman Leahy and Ranking Member Sessions:

On behalf of the Partnership for a Drug-Free America, I write to express enthusiastic support for the nomination of Dr. A. Thomas McLellan for Deputy Director of the Office of National Drug Control Policy (ONDCP). The Partnership has worked closely with Dr. McLellan and we hold him in the highest esteem. He is one of the most knowledgeable scientists in the country on addiction issues and is an excellent choice for Deputy Director.

The Partnership is an organization dedicated to helping parents prevent and address drug and alcohol issues and the disease of addiction in preteens, teens and young adults. Dr. McLellan has been our lead partner in building an on-line resource center for parents and other caregivers to help them at all points on the drug and alcohol use continuum -- from first talking to their kids about the dangers of drugs to finding help for a teen in crisis. As part of this effort, Dr. McLellan and his team at the Treatment Research Institute have helped us translate the latest scientific findings on teen brain development and behavior so parents can better understand what they can do to keep their child healthy and safe. Dr. McLellan's ability to communicate complicated science in an easily understandable way will be a great service in his work at the ONDCP.

As the Deputy Director of ONDCP, Dr. McLellan will play a lead role in shaping our national drug control strategy. His expertise in treatment, prevention and the role of addiction in criminal behavior will be invaluable in that process. He will have our full support and cooperation.

For these reasons the Partnership for a Drug-Free America respectfully urges the Committee to act swiftly to confirm the nomination of Dr. A. Thomas McLellan for Deputy Director of the Office of National Drug Control Policy.

Sincerely,

Stephen J. Pasierb
President and CEO

405 Lexington Avenue • New York, NY 10174 • Phone (212) 922-1560 • Fax (212) 922-1570 • www.drugfree.org

The Supreme Court of Montana

Office of the Court Administrator

PARK AVENUE BUILDING
301 SOUTH PARK, SUITE 328
PO BOX 203005
HELENA, MONTANA 59620-3005
TELEPHONE (406) 841-2950
Fax (406) 841-2955

JUSTICE BUILDING – ROOM 315
215 NORTH SANDERS
PO BOX 203002
HELENA, MONTANA 59620-3002
TELEPHONE (406) 444-2621
Fax (406) 444-0834

June 219, 2009

United States Senator Patrick Leahy
433 Russell Senate Office Building
United States Senate
Washington, DC 20510

Dear Senator Leahy:

I am writing you to express my support for the nomination of Dr. Andrew Thomas McLellan to the position of Deputy Director for Demand Reduction at ONDCP.

Moreover, I want to express to you how important it is that Dr. McLellan be fast-tracked through the confirmation process.

Tom McLellan is known throughout the alcohol and other drug treatment field as the premier researcher in the area. He is the most well respected researcher in the world when it comes to treatment and the demand reduction area. Tom has first hand experience regarding the devastation caused by drug dependency as it has been very close to him familial-wise.

But to the heart of the problem, drug abuse is the number one issue in this country. It drives most of the offenses in the criminal justice system, results in over 200,000 deaths a year and a substantial portion of the admissions to emergency rooms. It is a major cause of foreign affairs problems, Mexico gang wars being only one of them. And the list of problems caused by alcohol and other drug abuse and dependency goes on and on. You know this, no one has to tell you.

We need Tom's confirmation fast tracked for two primary reasons:

1. President Obama is experiencing substantial popularity at this point in time. As a result of this, the President is in a very favorable position to appeal to our citizens with alcohol and other drug dependencies to resolve their problems and get in to treatment, that their continued addiction is causing them great personal harm and this country great problems and they can help resolve them. I believe a direct appeal from the President at this point in time could have substantial impact. We need a person in the position that can strategize around this issue and take advantage of the popularity of the President before it is too late.
2. We are losing the battle over the insidious drug, marijuana. I have been in this field for 40 years as a state alcohol and drug abuse director in three different states, the drug court administrator in St. Louis, Missouri and currently as the statewide drug court administrator in Montana. I can tell you that marijuana is a major problem in this country. It is the first illicit drug used in the hierarchy of illicit drug use and the one of the most difficult to give up. I continually am amazed at the inability of offenders to be able to stop using marijuana and it is often the first drug they go back to and it gets them into trouble. Ethan Nadleman has 45 staff funded by George Soros

whose sole goal is to normalize the use of this dangerous drug by either legalizing it for medical purposes (the AMA says there is always a better alternative than marijuana for medical problems), legalizing it for industrial use and related purposes, legalizing it for tax revenue purposes and to reduce the people in jail and prison (nobody goes to jail or prison for simple possession of marijuana), and anything else they can think of. When in fact, their sole purpose is to legalize it so they and others in the country can continue to get high on the drug. Ethan Nadleman is being successful because we do not have the ammunition to fight back. Tom McLellan understands all of this and has a strategy to fight back and turn the tide. We have organizations nation-wide ready to fight this battle but the accumulation of the research in one place in the proper format is not available to us. **We need Tom McLellan in this position right now.**

Senator Leahy, I hope you agree with me and will do everything possible to move Tom's confirmation forward as soon as possible. Thank you for your consideration.

Sincerely,

Jeffrey N. Kushner
Statewide Drug Court Administrator

AMERICAN ACADEMY OF CHILD & ADOLESCENT PSYCHIATRY

Council

President
Robert L. Hendren, D.O.

President-Elect
Laurence L. Greenhill, M.D.

Secretary
David B. Herzog, M.D.

Treasurer
William Bernet, M.D.

Chair, Assembly
of Regional Organizations
of Child and Adolescent Psychiatry
Martin J. Drell, M.D.

Past President
Thomas F. Anders, M.D.

Tami D. Benton, M.D.
J. Michael Houston, M.D.
Paramjit T. Joshi, M.D.
Christopher J. Kratochvil, M.D.
Louis J. Kraus, M.D.
Alice R. Mao, M.D.
Yiu Kee Warren Ng, M.D.
Guy K. Palmes, M.D.
Kenneth M. Rogers, M.D.
Dorothy E. Stubbe, M.D.

Jerry M. Wiener Resident Member
Daniel L. Lafleur, M.D.

John E. Schowalter Resident Member
Glen P. Davis, M.D.

Executive Director
Virginia Q. Anthony

Journal Editor
Andres Martin, M.D.

AACAP News Editor
WunJung Kim, M.D.

Program Committee Chair
Neal D. Ryan, M.D.

Robert L. Stubblefield
Resident Fellow to AMA HOD
Kayla Pope, M.D.

July 8, 2009

The Honorable Patrick Leahy, Chairman
Committee on the Judiciary
United States Senate
224 Dirksen Senate Office Building
Washington, DC 20510

Dear Chairman Leahy,

On behalf of the American Academy of Child and Adolescent Psychiatry (AACAP), I write in full support of Dr. A. Thomas McLellan's nomination to become the next Deputy Director of the Office of National Drug Control Policy.

Dr. McLellan has spent a career promoting better understanding of addition and substance abuse, its causes and treatment, and has aided in de-stigmatizing the issue. He has been a promoter of early identification and prevention, with more than 400 scholarly publications in the area, and is currently a professor of psychiatry at the University of Pennsylvania and founder and Executive Director of the Treatment Research Institute, a not-for-profit research and evaluation institute in Philadelphia. As a leader in the addition field, Dr. McLellan has an expertise that will complement the President's agenda. His experience—research and clinical—is crucial in continuing to reduce illicit drug use, related crime and violence, and substance abuse health consequences.

The AACAP encourages the Judiciary Committee to schedule a vote on Dr. McLellan's nomination shortly and that a full Senate will confirm him with all deliberate speed. Again, the AACAP is pleased to support Dr. McLellan's nomination and looks forward to its continuous work with the Office of National Drug Control Policy.

Sincerely,

Robert L. Hendren

Robert L. Hendren, D.O.
President

3615 Wisconsin Avenue, NW
Washington, DC 20016-3007
202.966.7300 800.333.7636
Fax 202.966.2891
Email: executive@aacap.org
http://www.aacap.org

AMERICAN PSYCHOLOGICAL ASSOCIATION

July 9, 2009

The Honorable Patrick Leahy
Chairman
Committee on the Judiciary
United States Senate
224 Dirksen Senate Office Building
Washington, DC 20510

The Honorable Jeff Sessions
Ranking Member
Committee on the Judiciary
United States Senate
152 Dirksen Senate Office Building
Washington, DC 20510

Dear Chairman Leahy and Ranking Member Sessions,

On behalf of the organizations listed below, we want to thank you for holding Dr. Tom McLellan's confirmation hearing on June 24th for the position of Deputy Director of the Office of National Drug Control Policy. We hope that you will schedule a Judiciary Committee vote on Dr. McLellan's nomination as soon as the Committee's calendar permits and that a full Senate vote will follow soon thereafter.

We are delighted that President Obama has nominated a scientist of Dr. McLellan's stature, who also has such a visionary and practical approach to rational policy-making, to serve as Deputy in the Office of National Drug Control Policy. The public health of our nation will be very well-served by Dr. McLellan's appointment and we appreciate your stewardship during the confirmation process.

Alphabetical List of Organizational Endorsements:

Alcohol Policies Project, Center for Science in the Public Interest
American Academy of Addiction Psychiatry
American Academy of Child and Adolescent Psychiatry
American Osteopathic Academy of Addiction Medicine
American Psychological Association
American Society of Addiction Medicine
American Sociological Association
Association for Behavioral Health and Wellness
Association for Medical Education and Research in Substance Abuse
Association for Psychological Science
Betty Ford Center
Bradford Health Services
Center for Integrated Behavioral Health Policy
College on Problems of Drug Dependence
Community Anti-Drug Coalitions of America
Consortium of Social Science Associations
Drug Strategies
Entertainment Industries Council, Inc.

750 First Street, NE
Washington, DC 20002-4242
(202) 336-6067
(202) 336-6063 (Fax)
gmumford@apa.org

Geoffrey K. Mumford, Ph.D.
Associate Executive Director for Government Relations
Science Directorate

Faces and Voices of Recovery
Federation of Associations in Behavioral and Brain Sciences
Friends of the National Institute on Alcohol Abuse and Alcoholism
Friends of the National Institute on Drug Abuse
Friends Research Institute, Inc.
Hazelden Foundation
Hepatitis Foundation International
International Nurses Society on Addictions
Legal Action Center
Mental Health and Substance Abuse Corporations of Massachusetts, Inc.
NAADAC, The Association for Addiction Professionals
National Association for Children of Alcoholics
National Association for Children's Behavioral Health
National Association of Addiction Treatment Providers
National Association of Community Health Centers
National Association of Drug Court Professionals
National Association of Nurse Practitioners in Women's Health
National Association of State Alcohol and Drug Abuse Directors
National Center on Addiction and Substance Abuse at Columbia University
National Council for Community Behavioral Healthcare
National Council on Alcoholism and Drug Dependence, Inc.
National Families in Action
Operation PAR
Partnership For a Drug-Free America
Physicians and Lawyers for National Drug Policy
Research Society on Alcoholism
State Associations of Addiction Services
Therapeutic Communities of America

cc: The Honorable Harry Reid, Senate Majority Leader
The Honorable Mitch McConnell, Senate Minority Leader
The Honorable Orrin Hatch, Committee on the Judiciary
The Honorable Herbert Kohl, Committee on the Judiciary
The Honorable Dianne Feinstein, Committee on the Judiciary
The Honorable Charles Grassley, Committee on the Judiciary
The Honorable Russ Feingold, Committee on the Judiciary
The Honorable Jon Kyl, Committee on the Judiciary
The Honorable Lindsey Graham, Committee on the Judiciary
The Honorable Charles Schumer, Committee on the Judiciary
The Honorable John Cornyn, Committee on the Judiciary
The Honorable Richard Durbin, Committee on the Judiciary
The Honorable Benjamin Cardin, Committee on the Judiciary
The Honorable Tom Coburn, Committee on the Judiciary
The Honorable Sheldon Whitehouse, Committee on the Judiciary
The Honorable Amy Klobuchar, Committee on the Judiciary
The Honorable Ted Kaufman, Committee on the Judiciary
The Honorable Arlen Specter, Committee on the Judiciary
The Honorable Al Franken, Committee on the Judiciary